0001019687-15-004481.txt : 20151211 0001019687-15-004481.hdr.sgml : 20151211 20151211081705 ACCESSION NUMBER: 0001019687-15-004481 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20151210 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151211 DATE AS OF CHANGE: 20151211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SIMULATIONS PLUS INC CENTRAL INDEX KEY: 0001023459 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 954595609 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32046 FILM NUMBER: 151282154 BUSINESS ADDRESS: STREET 1: 42505 10TH STREET WEST STREET 2: * CITY: LANCASTER STATE: CA ZIP: 93534-7059 BUSINESS PHONE: 661-723-7723 MAIL ADDRESS: STREET 1: 42505 10TH STREET WEST CITY: LANCASTER STATE: CA ZIP: 93534-7059 8-K 1 simulations_8k.htm CURRENT REPORT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

December 10, 2015

(Date of the earliest event reported)

 

 

 

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

 

 

California 001-32046 95-4595609
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

 

 

42505 10th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

 

 

661-723-7723

Registrant's telephone number, including area code

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

 

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

 

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

 

  
 

 

Item 8.01     Other Events

 

On December 10, 2015, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release announcing preliminary revenues for the first fiscal quarter of fiscal year 2016 ended November 30, 2015. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

 

 

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

 

This Current Report on Form 8-K may contain forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange Act. The forward-looking statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of future performance and are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate. Any forward-looking statements in this Current Report on Form 8-K do not constitute guarantees of future performance and involve a number of factors that could cause actual results to differ materially, including risks more fully described in our most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any forward-looking information contained in this Current Report or with respect to the announcements described herein.

 

 

Item 9.01     Financial Statements and Exhibits

 

(d)     Exhibits

 

99.1Press release issued on December 10, 2015.

 

 2 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  SIMULATIONS PLUS, INC.
   
Dated: December 11, 2015 By: /s/ John R. Kneisel
    John R. Kneisel
Chief Financial Officer

 

 

 

 

 

 

 

 

 

 3 

 

EX-99.1 2 simulations_8k-ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

For Further Information:

Simulations Plus, Inc.

42505 10th Street West

Lancaster, CA 93534-7059

 

CONTACT:

Simulations Plus Investor Relations Hayden IR
Ms. Renee Bouche Mr. Cameron Donahue
661-723-7723 651-653-1854
renee@simulations-plus.com cameron@haydenir.com

 

For Immediate Release:

December 10, 2015

 

Simulations Plus Reports Record Preliminary Revenues for First Quarter FY2016

 

LANCASTER, CA, December 10, 2015 Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for the first quarter of its fiscal year 2016, ending November 30, 2015 (1QFY16).

 

Mr. John Kneisel, chief financial officer of Simulations Plus, Inc., stated: “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 1QFY16. This is the first quarter where we have truly comparable results, showing pure organic growth of the combined entity since our acquisition of our Buffalo division (Cognigen). Earnings will not be released until just prior to the filing of our quarterly report on Form 10-Q. We expect to file our 10-Q with the U.S. Securities and Exchange Commission on or before the January 14, 2016 deadline.”

 

Preliminary results for the quarter:

·Preliminary revenues increased 17.9% or $731,000, to $4.81 million, compared to $4.09 million for the same period in 2015.
oSoftware and software-related services increased $349,000 or 12.3% to $3.19 million or 66.2% of revenues for 1QFY16 compared to 1QFY15
oConsulting service revenues increased $382,000 or 30.6% to $1.63 million or 33.8% of revenues for 1QFY16 compared to 1QFY15
§Preliminary revenues in our Buffalo division increased $264,000 or 23% to $1.4 million for 1QFY16 compared to 1QFY15
·During 1QFY16, the company added 19 new software customers.
·Cash as of November 30, 2015, was $7.16 million after the Company made a dividend distribution of approximately $850,000 on November 16, 2015.

 

John DiBella, vice president for marketing and sales of Simulations Plus, said: “FY16 is off to a strong start, as we saw substantial gains in revenue from both software licenses and consulting services. An encouraging sign was the diversity of the new customers, as small and large pharmaceutical companies, plus several in the chemicals market, licensed our technology and/or utilized our consulting services. With training workshops scheduled around the world and at several regulatory agencies, in 2016, we hope to educate more scientists and continue this consistent expansion of our client base.”

 

 1 
 

 

About Simulations Plus, Inc.

 

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

 

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

 

Follow us on Twitter

 

###

 

 

 

 

 

 

 2 

 

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end